NCT Number: NCT07302087
Hemorrhagic syndromes are investigated using algorithms established by reference centers and hemostasis societies.
The investigation of platelet dense granules (nucleotide and serotonin testing) is part of the second-line tests.
It can be performed in cases of platelet aggregation abnormalities in platelet-rich plasma (PRP) suggesting a secretion abnormality, or in cases where the latter is normal, it can be performed if the patient's clinical presentation points to a primary hemostasis abnormality and the clinician wishes to pursue further investigations Intraplatelet serotonin deficiencies are often iatrogenic and may be accompanied by bleeding.
Their impact on platelet function is poorly documented.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Strasbourg, 67091, France
Location status: Recruiting
AMANDINE ROBERT, MD
SUB_INVESTIGATOR
ARNAUD DUPUIS, MD
SUB_INVESTIGATOR
DIHIA CHEBBAH, MD
SUB_INVESTIGATOR
Dominique Desprez, MD
CONTACT
Dominique Desprez, MD
PRINCIPAL_INVESTIGATOR
LAURENT SATTLER, MD
PRINCIPAL_INVESTIGATOR
OLIVIER FEUGEAS, MD
SUB_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 12 months
ISTH BAT bleeding questionnaire with its 12-item grid scored from 0 to 4:
A score ≥ 4 in men or ≥ 6 in women makes the presence of a constitutional hemostasis disorder highly probable
Contact information is provided by the study sponsor or research team.
University Hospital, Strasbourg, France
Other
Acronym: SEROTSTG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
